Rezolute's Phase 3 upLIFT study shows 75% responder rate at interim analysis

Rezolute reported interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, with 6 of 8 enrolled participants meeting the primary endpoint of 50% reduction in glucose requirements. Topline results are expected in H2 2026, potentially supporting a regulatory pathway for this ultra-rare disease treatment.